Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit

Compugen (CGEN) will present its UnigenX platform at the PEGS Europe Summit on November 18, 2026, in Lisbon, Portugal.

Rhea-AI Summary

Compugen (CGEN) will present its UnigenX platform at the PEGS Europe Summit on November 18, 2026, in Lisbon, Portugal. The oral presentation will be delivered by Dr. Roy Granit, Head of Computational Discovery, at 18:30 GMT.

UnigenX expands the company's computational discovery platform into targeted immune activation approaches, including T cell engagers. The company says the platform is designed to discover new tumor-associated antigen targets and combinations for selective targeting of tumor cells. The presentation is part of the summit's track on advancing multispecific antibodies and combination therapy to the clinic.

Key Terms

t cell engagers, tumor-associated antigen, bispecific antibody, blinded randomized

4 terms

t cell engagers medical

"such as T cell engagers, designed to discover novel tumor-associated antigen targets"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

tumor-associated antigen medical

"novel tumor-associated antigen targets and combinations for selective targeting"

Molecules—often proteins—found on the surface or inside cancer cells that the immune system can recognize as abnormal; some are largely unique to tumors while others also appear at low levels on healthy tissue. Investors care because these markers are targets for diagnostics, immunotherapies and vaccines, so showing a reliable, targetable marker is like putting a bull's-eye on a disease: it can speed development, raise the value of a drug program and influence regulatory and commercial prospects.

bispecific antibody medical

"Rilvegostigom, a PD-1/TIGIT bispecific antibody"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

blinded randomized medical

"currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial"

A blinded randomized study is a clinical trial in which participants are assigned to treatment groups by a chance process (randomization) and one or more parties involved in the trial do not know which treatment each participant receives (blinding). Randomization ensures treatment groups are comparable by distributing known and unknown factors by chance, while blinding prevents the expectations or behavior of participants, clinicians, or outcome assessors from influencing results; common forms are single-blind (usually participants unaware), double-blind (participants and clinicians or assessors unaware), and triple-blind (additional trial staff or analysts unaware). Blinding can be broken or impractical for some interventions, and randomization does not on its own prevent problems like poor trial conduct or selective reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced an oral presentation at the 18^th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place November 16-19, 2026, in Lisbon, Portugal.

The presentation will showcase UnigenX™, an expansion of the Company's computational discovery platform into targeted immune activation modalities, such as T cell engagers, designed to discover novel tumor-associated antigen targets and combinations for selective targeting of tumor cells. 

Title: UnigenX™: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation
Track: Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Speaker: Dr. Roy Granit, Head of Computational Discovery at Compugen
Date & Time: Wednesday, November 18, 2026 at 18:30 GMT
Link: PEGS Europe 2026

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Lindsey Trickett 
Email: LindseyT@cgen.com 
Tel: +1 415 373 0892

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-unigenx-platform-at-the-18th-annual-pegs-europe-summit-302934740.html

SOURCE Compugen Ltd.